Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection
AssigneeISA Pharmaceuticals B.V.
InventorsWilhelmus Johannes Theodorus Alexander KREBBER, Johan Herman KESSLER, Cornelis Joseph Maria MELIEF, Kitty Michelle Corinne KWAPPENBERG
Life of this patent
Estimating the term…
Abstract
The present invention relates to the fields of medicine and immunology. In particular, it relates to novel peptides that may be used in the treatment and/or prevention of a Hepatitis B viral infection and/or an Hepatitis B related disease or condition.
Claims23
A method for the prevention and/or treatment of an HBV-related disease comprising administering to a subject an effective amount of a peptide of at least 30 and at most 40 amino acids in length and comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 51-79, 1142-1145 and 1468-1471.
A method for the prevention and/or treatment of an HBV-related disease comprising administering to a subject an effective amount of a polynucleotide encoding a peptide of at least 30 and at most 40 amino acids in length, the peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 51-79, 1142-1145 and 1468-1471.
The method according to claim 13, wherein the administration comprises administration of an additional polynucleotide and/or of a peptide as defined in claim 18.
Dependencies are inferred from the claim text.